FDA issues Complete Response Letter for deramiocel

What this means

Deramiocel is an experimental cell therapy designed to treat heart damage by using modified cells to help repair tissue. The FDA declined to approve the therapy, citing unresolved issues in Capricor's application that need addressing before reconsideration. This delay means patients waiting for a new treatment option will have to hold out longer while the company works to resolve the agency's concerns.